Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 7.4% - Should You Sell?

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s share price was down 7.4% during mid-day trading on Wednesday . The company traded as low as $127.93 and last traded at $127.20. Approximately 59,745 shares were traded during trading, a decline of 87% from the average daily volume of 473,383 shares. The stock had previously closed at $137.41.

Analysts Set New Price Targets

Several brokerages have recently commented on ASND. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target for the company. The Goldman Sachs Group increased their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research note on Tuesday, February 18th. Cantor Fitzgerald increased their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Finally, Evercore ISI lifted their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of "Moderate Buy" and an average target price of $204.64.

Remove Ads

Ascendis Pharma A/S Stock Performance

The firm has a fifty day simple moving average of $148.33 and a 200-day simple moving average of $137.63. The firm has a market cap of $9.48 billion, a price-to-earnings ratio of -21.90 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. Analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. bought a new position in Ascendis Pharma A/S in the 4th quarter valued at about $28,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. grew its position in shares of Ascendis Pharma A/S by 415.2% in the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after buying an additional 328 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after acquiring an additional 214 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.